Word: turn
(lookup in dictionary)
(lookup stats)
Dates: during 1990-1999
Sort By: most recent first
(reverse)
...though, was helping blacks register to vote at a time when that was perilous work. In 1960 fewer than 100 of Forrest County's 8,000 voting-age blacks were registered. Dahmer would drive neighbors to the courthouse and watch in frustration as the white registrar found reasons to turn them away. Eventually, Dahmer got the sheriff to sign out to him a poll-tax receipt book, and Dahmer announced over the radio that blacks could register at his grocery. "I said, 'I wouldn't do this if I were you,'" recalls J.C. Fairley, a friend and fellow N.A.A.C.P. activist...
Stumbling blocks lie all along the way. Sometimes the clinical trials are badly designed; a new medication may be given in the wrong dosage, or delivered to the wrong subset of patients. And even when everything's done right, chemicals that looked highly promising in laboratory animals often turn out to be dangerous or ineffective. Most experimental compounds never get out of the lab. And for every five drugs that do go into clinical testing, only one is eventually approved...
...overruled by the rank and file. Some dismiss the chairman's fears that the campaign against bilingual education will spawn a Prop. 187-style backlash. They point to polls showing that a majority of Latinos actually support the initiative. But Latino political analysts warn that one thing could still turn their community against the measure: a close association with the California Republican Party...
...mainly because of the risks, which haven't changed much. But some other things have changed, a lot. The overall market has roared ahead while biotech stocks barely budged, creating a vastly wider gap in value, and the biotech industry has had more time to mature. It will probably turn net profitable next year, and, notes money manager Stephen Flaks in Scottsdale, Ariz., "there are now hundreds of drugs that will be on the market within two years." Companies with such drugs are among Flaks' favorites: Matrix Pharmaceuticals (cancer), Neurocrine Biosciences (Alzheimer's) and Imclone Systems (cancer...
When Dr. Judah Folkman is asked whether he can cure cancer, he invariably replies, "Yes, in mice." That's not entirely self-effacing whimsy. Like every good researcher--and every responsible science journalist--he knows all too well that most drugs that work in lab animals turn out to be duds in humans. The field is littered with "magic bullets" that failed, among them monoclonal antibodies, tumor necrosis factor, interferon and interleukin-2. While all were initially hyped as potential cure-alls, they have turned out to have only modest usefulness in the war on cancer. At best, says...